NCT02000440 - A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

May 11, 2016

Conditions

Glomerulosclerosis, Focal Segmental

Interventions

DRUG

Losmapimod

Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, biconvex, plain faced, tablet. Oral doses of losmapimod, 7.5 mg (1 tablet) or 15 mg (2 tablets), will be taken twice daily (BID) with food and swallowed whole (not chewed or crushed)

Trial Locations (12)

19140

GSK Investigational Site, Philadelphia

43210

GSK Investigational Site, Columbus

44109

GSK Investigational Site, Cleveland

48109

GSK Investigational Site, Ann Arbor

70112

GSK Investigational Site, New Orleans

90025

GSK Investigational Site, Los Angeles

94304

GSK Investigational Site, Stanford

27599-7155

GSK Investigational Site, Chapel Hill

T6G 2B7

GSK Investigational Site, Edmonton

V6Z 1Y6

GSK Investigational Site, Vancouver

M4N 3M5

GSK Investigational Site, Toronto

M5G 2C4

GSK Investigational Site, Toronto